News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
StockStory Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Pediatrix Medical Group, Inc. (MD). The funds are sorted by market value and include details such as issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The compilation aims โฆ
Pediatrix Medical Group (MD) recently reported strong Q2 2026 results with increased sales and net income, alongside significant share repurchases. These actions support per-share metrics amidst ongoing challenges like reimbursement risk and physician cost inflation. While the company projects revenue growth and a fair โฆ
This article details an SEC Form 144 filing by Pediatrix Medical Group, Inc. (MD) on August 14, 2026. The filing indicates a proposed sale of 18,500 shares of common stock with an aggregate market value of $491,868 by an undisclosed individual, through Merrill Lynch. โฆ
Pediatrix Medical Group (MD) director Shirley A. Weis was granted 472 restricted shares of common stock on August 12, 2026, under the company's 2008 Incentive Compensation Plan. These shares, valued at $26.50 each, will vest on May 7, 2027, and increase Weis's direct holdings โฆ
John M. Starcher Jr., a director at Pediatrix Medical Group (MD), was granted 472 restricted shares of common stock on August 12, 2026. These shares, valued at $26.50 each, are part of the company's incentive compensation plan and will vest on May 7, 2027. โฆ
Pediatrix Medical Group director Thomas McEachin was granted 472 restricted shares of common stock on August 12, 2026, valued at $26.50 per share, under the company's incentive plan. These shares will vest on May 7, 2027. Following this transaction, his direct holdings increased to โฆ
Pediatrix Medical Group (MD) director Guy P. Sansone received an equity award of 472 restricted shares on August 12, 2026, priced at $26.50 per share. These shares, granted under the company's Second Amended and Restated 2008 Incentive Compensation Plan, will vest on May 7, โฆ
Pediatrix Medical (MD) is presented as a smart investment due to its strong year-to-date performance, strategic acquisitions, and robust financial metrics like an 11.6% return on invested capital. The company benefits from improved cash collections, a favorable payer mix, and higher patient acuity in โฆ
The average 12-month price target for Pediatrix Medical Group, Inc. (MD) stock has been lowered from $26.17 to $26 by 5 analysts, with a range of $21 to $28 per share. This new target suggests a potential 2% downside from the August 12 closing โฆ
Wasatch Advisors LP increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 21.9% in the second quarter, holding 2.50 million shares valued at approximately $63.3 million. Institutional investors now own 97.71% of the company's stock, which recently reported strong quarterly earnings, beating revenue โฆ
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Mark Ordan Chief Financial Officer - Kasandra Rossi Full Conference Call Transcript Operator: Thank you for standing by. My name is Jordan, and I'll โฆ
Pediatrix Medical Group (MD) has seen an 89% share price return over the past year, yet its stock appears undervalued based on several valuation metrics, including a P/E ratio significantly below the healthcare sector average. Despite a recent share price drop post-earnings, the company โฆ
Pediatrix Medical Group reported a modest profit uptick in Q2 and H1 2026, with increased sales and net income. This suggests improved operational efficiency, but the company's investment narrative remains focused on navigating reimbursement and labor pressures. While share buybacks and earnings growth are โฆ
Pediatrix Medical Group (MD) reported stronger Q2 2026 results with increased sales and net income, leading to improved EPS from continuing operations. These results, along with the company's inclusion in Russell 2000 Defensive indexes, support its investment narrative of disciplined cost control in the โฆ
Sei Investments Co. reduced its stake in Pediatrix Medical Group Inc. (NYSE:MD) by 19.3% in the first quarter, selling 37,564 shares and retaining 157,407 shares valued at $3.37 million. Despite institutional selling and buying from various firms, the company reported strong Q1 earnings of โฆ
Pediatrix Medical Group (MD) reported strong second-quarter 2026 earnings, surpassing analyst estimates due to improved cash collections, a favorable payor mix, and recent acquisitions. Despite higher operating costs and lower patient volumes, the company saw an 18.9% increase in adjusted EPS and a 4.1% โฆ
Deutsche Bank has updated its price target for Pediatrix Medical to $25, an increase from the previous target of $19. Despite the raised price target, the firm has decided to maintain its Hold rating on the company's stock. This adjustment reflects an updated valuation โฆ
This article analyzes insider selling at Pediatrix Medical Group (NYSE:MD) totaling US$1.8m over the last year, particularly a large sale by the CEO, which could signal potential weakness in the company's future performance. Despite the stock price being down 23% in the past 12 โฆ
Pediatrix Medical Group (NYSE: MD) reported a 4.0% year-over-year increase in Q2 2026 net revenue to $487.8 million, driven by recent acquisitions and improved reimbursement rates, despite a decline in patient volumes. While diluted GAAP EPS rose to $0.49, higher operating costs led to โฆ
Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 results that exceeded revenue and non-GAAP profit expectations, with sales up 4% year-on-year to $487.8 million and adjusted EPS of $0.63. Despite beating estimates, the stock dropped 12.3% post-announcement, indicating investor disappointment. The company highlighted strong performance โฆ
Pediatrix Medical Group (NYSE: MD) reported Q2 revenue that beat analyst estimates, driven by recent acquisitions and improved reimbursement factors, despite a decrease in patient volumes. The company also reaffirmed its 2026 full-year Adjusted EBITDA outlook. Analysts currently rate the stock as a "buy" โฆ
Pediatrix Medical Group (NYSE: MD) reported Q2 2026 adjusted EBITDA of $76 million, reaffirming its full-year outlook of $280-$300 million. The company's same-unit revenue grew due to strong RCM collections, improved payer mix, and higher patient acuity, despite a decline in NICU days. Pediatrix โฆ
Pediatrix Medical Group, Inc. (MD) reported Q2 adjusted EPS of $0.63 per share, surpassing FactSet's estimate of $0.59. The article provides a snapshot of the company's recent performance and mentions its Q2 2026 earnings call scheduled for August 4, 2026. Further details about the โฆ
Pediatrix Medical Group exceeded Q2 2026 earnings and revenue estimates, reporting adjusted EPS of $0.63 on $488 million in revenue, compared to analyst expectations of $0.60 and $478.49 million. Despite the beat, shares slipped 1.1% in early trading, influenced by softer patient volumes and โฆ
Pediatrix Medical Group reported strong second-quarter 2026 results with net revenue of $488 million and Adjusted EPS of $0.63, exceeding expectations. The company attributes this performance to recent acquisitions and improved reimbursement metrics, despite a 2.1% decrease in same-unit patient volume. Pediatrix reaffirmed its โฆ
Pediatrix Medical Group (MD) is set to report its Q2 earnings this Tuesday. The market expects a 1.9% year-on-year revenue growth, a turnaround from last year's decrease. The company has a strong track record of beating revenue estimates, and analysts have reconfirmed their expectations โฆ
Pediatrix Medical Group Inc. is expected to report strong second-quarter results, with analysts predicting 60 cents per share on revenue of $478.49 million, signaling significant sequential acceleration. The company has distinguished itself by avoiding the reimbursement pressures affecting other healthcare providers, maintaining a stable โฆ
This article provides a technical analysis of Pediatrix Medical Group Inc (MD), focusing on its price momentum, support, resistance levels, and various technical indicators. It notes that MD's current stock price is trading between resistance at $28.32 and support at $24.25, suggesting suitability for โฆ
This article provides a risk assessment for Pediatrix Medical Group Inc (MD), noting its current risk score of 5.98, ranking it 34 out of 75 in the Healthcare Providers & Services industry. The company has a beta value of 0.70, indicating it tends to โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States